Top 20 Innovative Immuno-Oncology Companies in the US

Post by
Top 20 Innovative Immuno-Oncology Companies in the US

The immuno-oncology market has grown at a compound rate of 10%, from $57 billion to $69 billion in 2021. It is expected to reach around $98 billion by 2025.

This is a highly competitive market, so companies in this sector have to innovate rapidly by creating novel drugs and therapies.

Here are the top 20 innovative immuno-oncology companies in the US:

Allogene Therapeutics

Located in California, Allogene Therapeutics is a clinical-stage biotechnology company specializing in developing allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer treatment. The company's pipeline includes several allogeneic CAR T therapies and UCART19 which is intended for the treatment of acute lymphoblastic leukemia (ALL).


Asher Biotherapeutics 

Located in California, Asher Biotherapeutics develops targeted immunotherapies to treat cancer and other diseases. Their cis-targeting platform enables the activation of immune cell types to take on cancer cells with minimum side effects. 


Rubius Therapeutics

Located in Massachusetts, Rubius Therapeutics is a pioneer in developing Red Cell Therapeutics™ (RCTs) using their proprietary RED PLATFORM™. The RCTs are potent, selective, and ready-to-use cellular therapies that can be used to treat autoimmune diseases and cancer.


Marengo Therapeutics

Located in Massachusetts, Marengo Therapeutics is a pioneer in developing therapies that boost the body's immune system to fight cancer. Using their proprietary therapeutic platform, the company boosts the patient's T cells to amplify their anti-tumor activity while promoting long-lasting immunity 


Catamaran Bio

Located in Massachusetts, Catamaran Bio develops off-the-shelf, allogeneic immune cell therapies that are safe and effective using their proprietary TAILWIND™ platform to treat cancer and immune disorders. 


Fate Therapeutics

Located in California, Fate Therapeutics is a clinical-stage biopharmaceutical company developing cellular immunotherapies for cancer and immune disorders. Their therapy pipeline includes natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to work in conjunction with current cancer therapies such asimmune checkpoint inhibitors and monoclonal antibodies. Its other product candidate is ProTmune™, which is currently being evaluated in the Phase 2 clinical trial to prevent graft-versus-host disease.


Gritstone bio

Located in California, Gritstone bio develops custom immunotherapies to treat different kinds of cancer and infectious diseases. Its current pipeline offers products such as BiSAb and SLATE that are intended to treat solid tumors 

Genocea

Located in Massachusetts, Genocea uses its proprietary ATLAS™ platform to select and identify therapeutically relevant antigens that drive powerful anti-tumor immune responses using the patient's T cells.

Odyssey Therapeutics

Located in Massachusetts, Odyssey Therapeutics aims to create next-generation precision medicine for patients with cancer and inflammatory diseases. The Odyssey team can quickly identify relevant targets and optimize therapeutic assets for clinical development using their in-house intellectual capital.


Apexigen

Located in California, Apexigen is a clinical-stage biopharmaceutical company that uses it's proprietary antibody drug discovery platform to develop drugs that enhance tumor-specific immunity.

Artiva Biotherapeutics

Located in California, Artiva develops off-the-shelf therapies like allogeneic NK cell therapies, including CAR-NK cell therapies designed to treat solid tumors or hematologic malignancies. Their mission is to deliver safe and easily accessible cancer therapies to patients.

Filtricine

Located in California, Filtricine has developed targeted nutrient deprivation (TND) therapy, which focuses on taking away nutrients critical for the growth of cancer cells. This helps to exploit metabolic dependencies to stop cancer from spreading.


OncoMyx Therapeutics

Located in Arizona, OncoMyx Therapeutics develops immunotherapies that create an immune response to fight cancer. It's proprietary myxoma platform targets hematologic and solid tumors with a unique oncolytic virus called myxoma and a novel patented systemic delivery approach


ArsenalBio

Located in California, ArsenalBio is a programmable cell therapy company that uses CRISPR-enabled genome editing to engineer living medicines that attack cancer and improve patient lives.


Pyxis Oncology

Located in Massachusetts, Pyxis Oncology develops biologics that overcome suppression and target tumor cells. They believe that antibody drug candidates (ADCs) and immunotherapies hold the potential to improve patient lives and target difficult-to-treat cancers. 


Arch Oncology

Located in California, Arch Oncology is a clinical-stage company that develops antibody therapies to treat hematologic malignancies and solid tumors. Their lead candidate AO-176 is used to treat patients with solid tumors and is currently going through Phase 1/2 clinical trials. AO-176 can directly kill tumor cells and induce DAMPs (Damage Associated Molecular Patterns), resulting in Immunogenic Cell Death.


Rakuten Medical

Located in California, Rakuten Medical is developing cell-targeting investigational therapies on its Illuminox™ technology platform. These therapies are known to demonstrate selective cell killing and tumor necrosis in preclinical studies. 


Triumvira Immunologics

Located in Texas, Triumvira Immunologics is developing a novel and proprietary T cell Antigen Coupler (TAC) technology that is thought to be safer and more effective than some of the current cancer treatments like antigen receptor (CAR) and engineered T cell receptor (TCR) therapies.


Inimmune

Located in Montana, Inimmune is developing next-generation immunotherapies for the treatment of autoimmunity and cancer.


Arcus Biosciences

Located in California, Arcus Biosciences is a clinical-stage biopharmaceutical company focused on developing therapies for cancer using the ATP-adenosine pathway, which is a crucial pathway associated with immunosuppression in a tumor microenvironment. The company's product pipeline includes Etrumadenant, AB680, and Domvanalimab.


Lab Management Software for Immuno-Oncology Companies: Scispot.io

Scispot has become the primary lab management software of choice for numerous modern biotech companies, including immuno-oncology startups.

Scispot creates a connected digital replica of these innovative bioscience companies. It centralizes their company-wide data, templatizes routine research and automates non-scientific tasks. It makes other lab software such as electronic lab notebooks (ELNs) and lab information management systems (LIMS) redundant.

Immuno-Oncology Companies use Scispot's operating platform to manage their research projects, inventory, samples, and partners all in one spot. Request a demo to learn how you can accelerate your research using Scispot.

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

Check Out Our Other Blog Posts